Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study in the Prevention of Antibiotic-Associated Diarrhea (AAD) and Clostridium Difficile-Associated Diarrhea (CDAD) in Hospitalized Adult Patients Exposed to Nosocomial Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Antibiotic therapy for a minimum of 3 days and a maximum of 14 days~* Expected to remain hospitalized for a minimum of 5 days~* Patients who have received less than 36 hours of antibiotic therapy~* Negative pregnancy test at screening~* Obtained his/her informed consent after verbal and written information~* Patients having a telephone available (mobile, work, home)~* Patients having a fridge at home~Exclusion Criteria:~* Pregnant or breastfeeding women~* Patients presenting with active diarrhea (3 or more liquid stools per 24 hour period).~* Patients with a history of daily consumption of probiotics, fermented milk and/or yogurt;~* Patients known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study product (i.e. Non-medicinal ingredients: Cellulose, hypromellose, magnesium stearate (vegetal source), ascorbic acid, Colloidal silicon dioxide)~* Patients presenting with an active, non-controlled intestinal disease such as Crohn's Disease or ulcerative colitis;~* A previous documented C. Difficile infection \< 3 months prior to study initiation ;~* Ostomized patients, parenteral nutrition users~* Patients with an immunosuppressive therapy or any health condition causing immunosuppression (including haematological malignancies, acquired immune deficiency syndrome (AIDS))~* Ongoing or recent use of antibiotic therapy in the 30 days prior to the study product first administration.~* Patients with planned administration of antibiotics other than broad spectrum Penicillin, Cephalosporin or Clindamycin for the treatment of an infection;~* Patients with concomitant participation in another clinical trial;~* Patients who are not likely to comply with study requirements

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two capsules of placebo (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
- BIO-K+ CL-1285 (Type: ACTIVE_COMPARATOR): Two probiotic capsules (BIO-K+ CL-1285®) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.
- BIO-K+ CL-1285® & placebo (Type: OTHER): One probiotic capsule (BIO-K+ CL-1285®) and one placebo capsule (devoid of microorganisms) per day. Patients took their daily dose 2h after breakfast and antibiotic administration each day. Patients were then followed for an additionnal 21 days after completion of the assigned intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).